Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood (IRWD) delivered earnings and revenue surprises of -32.26% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical...
Common stock will begin trading on a split-adjusted basis on July 5, 2022...
Brickell (BBI) delivered earnings and revenue surprises of -33.33% and 52.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments,...
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...
Assertio (ASRT) delivered earnings and revenue surprises of 122.22% and 10.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical...
Concert (CNCE) delivered earnings and revenue surprises of -7.53% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?